'''Viqualine''' ([[International Nonproprietary Name|INN]]) (developmental code name '''PK-5078''') is an [[antidepressant]] and [[anxiolytic]] [[drug]] that was never marketed.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=RA1-PA602|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=1–}}</ref><ref name="pmid3075725">{{cite journal |vauthors=Faravelli C, Albanesi G, Sessarego A |title=Viqualine in resistant depression: a double-blind, placebo-controlled trial |journal=Neuropsychobiology |volume=20 |issue=2 |pages=78–81 |year=1988 |pmid=3075725 |doi= 10.1159/000118477|url=}}</ref><ref name="PapakostasFava2010">{{cite book|author1=George I. Papakostas|author2=Maurizio Fava|title=Pharmacotherapy for Depression and Treatment-resistant Depression|url=https://books.google.com/books?id=zigp-66vq0MC&pg=PA304|year=2010|publisher=World Scientific|isbn=978-981-4287-59-3|pages=304–}}</ref> It acts as a potent and selective [[serotonin releasing agent]] and [[selective serotonin reuptake inhibitor|serotonin reuptake inhibitor]].<ref name="PapakostasFava2010" /><ref name="pmid6717757">{{cite journal |vauthors=Le Fur G, Imbault F, Mitrani N, Marquis F, Renault C, Dubroeucq MC, Gueremy C, Uzan A |title=The 5-hydroxytryptamine-releasing properties of two epimer quinoline derivatives |journal=Neuropharmacology |volume=23 |issue=2A |pages=169–73 |date=February 1984 |pmid=6717757 |doi= 10.1016/S0028-3908(84)80010-6|url=}}</ref> In addition, viqualine displaces [[diazepam]] from the [[GABAA receptor|GABA<sub>A</sub> receptor]] and produces [[benzodiazepine]]-like effects, indicating that it is also a [[positive allosteric modulator]] of the benzodiazepine site of the GABA<sub>A</sub> receptor.<ref name="PapakostasFava2010" /><ref name="FaravelliAlbanesi1988">{{cite journal|last1=Faravelli|first1=Carlo|last2=Albanesi|first2=Giorgio|last3=Sessarego|first3=Antonella|title=Viqualine in Resistant Depression: A Double-Blind, Placebo-Controlled Trial|journal=Neuropsychobiology|volume=20|issue=2|year=1988|pages=78–81|issn=1423-0224|doi=10.1159/000118477|pmid=3075725}}</ref> The drug has mainly been researched as a potential treatment for [[alcoholism]].<ref name="pmid2522667">{{cite journal |vauthors=Naranjo CA, Sellers EM |title=Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers |journal=Recent Developments in Alcoholism : an Official Publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism |volume=7 |issue= |pages=255–66 |year=1989 |pmid=2522667 |doi= |url=}}</ref><ref name="pmid2673621">{{cite journal |vauthors=Naranjo CA, Sullivan JT, Kadlec KE, Woodley-Remus DV, Kennedy G, Sellers EM |title=Differential effects of viqualine on alcohol intake and other consummatory behaviors |journal=Clinical Pharmacology and Therapeutics |volume=46 |issue=3 |pages=301–9 |date=September 1989 |pmid=2673621 |doi= 10.1038/clpt.1989.142|url=}}</ref>
